Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Believe it or not, there's something worse than male pattern baldness. It's depression, plunging libido and shrinking ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.

Telehealth companies like Hims & Hers (HIMS) are aggressively marketing hair-loss medications to young men, with some patients saying they ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...

Hims & Hers Health ( HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Hims & Hers stock has been a mega-outperformer for investors, growing more than 600% over the past year, largely on the back of its compounded semaglutide products that mimic the effect of Ozempic ...